N-(1-(3-(dimethylamino)phenyl)-6-(3-(dimethylamino)propoxy)-1H-benzo[d]imidazol-2-yl)benzamide | 1616475-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-(1-(3-(dimethylamino)phenyl)-6-(3-(dimethylamino)propoxy)-1H-benzo[d]imidazol-2-yl)benzamide
• CAS: 1616475-49-0
• 化学式: C₂₇H₃₁N₅O₂
• 分子量: 457.575
• InChiKey: WNLVRNKSCJUYBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.67
• 重原子数：
  34.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  62.63
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  N-(1-(3-(dimethylamino)phenyl)-6-(3-(dimethylamino)propoxy)-1H-benzo[d]imidazol-2-yl)benzamide 在 盐酸 作用下， 以 水 为溶剂， 反应 21.0h， 以27%的产率得到(1-(3-dimethylamino)phenyl)-6-(3-(dimethylamino)propoxy)-1H-benzo[d]imidazol-2-amine
  参考文献：
  名称：

  Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site

  摘要：

  We describe the exploration of N1-aryl-substituted benzimidazoles as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The design of the compounds was guided by the co-crystal structure of a benzimidazole viral translation inhibitor in complex with the RNA target. Structure-binding activity relationships of aryl-substituted benzimidazole ligands were established that were consistent with the crystal structure of the translation inhibitor complex. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.009
• 作为产物：
  描述：

  3-氟-4-硝基苯酚 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二异丙基乙胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 20.0~60.0 ℃ 、101.33 kPa 条件下， 反应 105.0h， 生成 N-(1-(3-(dimethylamino)phenyl)-6-(3-(dimethylamino)propoxy)-1H-benzo[d]imidazol-2-yl)benzamide
  参考文献：
  名称：

  Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site

  摘要：

  We describe the exploration of N1-aryl-substituted benzimidazoles as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The design of the compounds was guided by the co-crystal structure of a benzimidazole viral translation inhibitor in complex with the RNA target. Structure-binding activity relationships of aryl-substituted benzimidazole ligands were established that were consistent with the crystal structure of the translation inhibitor complex. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.009